By G HossainPosted on November 18, 2026Posted in Pharmaceutical & Bio Science, UncategorizedTagged bio science career, blogs, business career news, career tips, job blog, job news, RJF Pharmaceutical Jobs Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race. Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns Post navigation Government actions are hitting smaller biotechs the hardest: ReportThe firms that survive AI will think like Nintendo, not Kodak